Analysis

DiaMedica Therapeutics 2025 Financial Review

DiaMedica Therapeutics 2025 Financial Review

Company Overview DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on treatments for preeclampsia, fetal growth restriction, and acute ischemic…

VerifyMe 2025 Financial Results Analysis

Company Overview VerifyMe, Inc. provides brand protection and precision logistics solutions for time- and temperature-sensitive products. Key Financial Figures The…

Lantern Pharma 2025 Financial Update

Company Overview Lantern Pharma is an oncology company utilizing its AI platform, RADR, to advance precision drug development. It maintains…

Phreesia Q4 Fiscal 2026 Financial Review

Company Overview Phreesia, Inc. provides digital patient activation solutions, including tools for intake, outreach, and education, to enhance the patient…

HireQuest 2025 Financial Results

Company Overview HireQuest is a national franchisor offering on-demand staffing and executive search services across multiple industries. Key Financial Figures…

Palantir (PLTR) Looks Compelling on Paper — But These 3 Weaknesses Could Stall the Rally

Palantir Technologies has entered 2026 with a narrative that reads unusually clean: accelerating growth, a marquee AI product cycle, and…

Tesla (TSLA) Bets $2.9B on Chinese Solar Gear to Power U.S. AI Grid

Tesla (TSLA) is in talks to purchase roughly $2.9 billion (about 20 billion yuan) of solar manufacturing equipment from Chinese…

LM Funding America 2025 Financial Review

Company Overview LM Funding America, Inc. is a Florida-based Bitcoin treasury and mining firm. The company also operates a specialty…

Satellos Bioscience: 2025 Financial Performance

Company Overview Satellos Bioscience Inc. (NASDAQ: MSLE) is a clinical-stage biotechnology company focused on developing SAT-3247 to treat degenerative muscle…

Entera Bio: 2025 Annual Financial Summary

Company Overview Entera Bio is a clinical-stage leader developing oral peptide therapies, specifically focusing on its N-Tab® platform. Its lead…